SELLAS Life Sciences Group Enters Material Definitive Agreement
Ticker: SLS · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
SELLAS Life Sciences Group just signed a big deal, details TBD.
AI Summary
On October 3, 2024, SELLAS Life Sciences Group, Inc. entered into a material definitive agreement. The filing does not specify the nature of the agreement or any associated dollar amounts or specific parties involved.
Why It Matters
This filing indicates a significant new agreement for SELLAS Life Sciences Group, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details about the material definitive agreement introduces uncertainty regarding its implications for the company.
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- October 3, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by SELLAS Life Sciences Group?
The filing does not specify the nature of the material definitive agreement.
Who are the other parties involved in this material definitive agreement?
The filing does not disclose the names of the other parties involved in the agreement.
Are there any financial commitments or dollar amounts associated with this agreement?
The filing does not provide any specific dollar amounts or financial details related to the agreement.
When was this material definitive agreement officially entered into?
The earliest event reported in the filing related to this agreement is October 3, 2024.
Does this agreement represent a new partnership, acquisition, or other significant business development?
The filing states it is a 'material definitive agreement' but does not specify its exact purpose or type.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-10-04 16:06:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
Filing Documents
- tm2425562d1_8k.htm (8-K) — 28KB
- tm2425562d1_ex10-1.htm (EX-10.1) — 16KB
- 0001104659-24-106261.txt ( ) — 217KB
- sls-20241003.xsd (EX-101.SCH) — 3KB
- sls-20241003_lab.xml (EX-101.LAB) — 33KB
- sls-20241003_pre.xml (EX-101.PRE) — 22KB
- tm2425562d1_8k_htm.xml (XML) — 4KB
01 Entry into a
Item 1.01 Entry into a Material Definitive Agreement. On October 3, 2024, SELLAS Life Sciences Group, Inc. (the "Company"), as subtenant, entered into a Letter Agreement with Times Square Tower Associates LLC (the "Sublandlord") relating to a certain sublease (as amended) of certain premises located at Times Square Tower, 7 Times Square, New York, New York (the "Sublease"). The Letter Agreement provides for the extension of the expiration date of the Sublease from September 30, 2025 to September 30, 2026. The annual rent remains unchanged. The foregoing description of the Letter Agreement is qualified in its entirety by reference to the Letter Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference. 2
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Letter Agreement, effective October 3, 2024, by and between SELLAS Life Sciences Group, Inc. and Times Square Tower Associates LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: October 4, 2024 By: /s/ John T. Burns Name: John T. Burns Title: Senior Vice President, Chief Financial Officer 4